K. K. Pharma Solutions

1 INDICATIONS AND USAGE 1.1 X-linked Hypophosphatemia 1.2 Tumor-induced Osteomalacia 2 DOSAGE AND ADMINISTRATION 2.1 Important Information Prior to Initiation of CRYSVITA 2.2 Recommended Dosage for Pediatric Patients with X-linked Hypophosphatemia (6 months to less than 18 years of age) 2.3  Recommended Dosage for Adult Patients with X-linked Hypophosphatemia (18 years of age and older) 2.4 Recommended Dosage for Pediatric Patients with Tumor-induced Osteomalacia (2 years to less than 18 years of age) 2.5 Recommended Dosage for Adult Patients with Tumor-induced Osteomalacia (18 years of age and older) 2.6 Missed Dose 2.7 25-Hydroxy Vitamin D Supplementation 2.8 General Considerations for Subcutaneous Administration 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 5.1 Hypersensitivity 5.2 Hyperphosphatemia and Risk of Nephrocalcinosis 5.3 Hypercalcemia 5.4 Injection Site Reactions